0
Trillium Therapeutics Inc. Banner Image

Trillium Therapeutics Inc. has reached its limit for free report views

Work for Trillium Therapeutics Inc.? Upgrade Your Profile and unlock all your annual reports.

Trillium Therapeutics Inc.

  • Ticker TRIL
    Exchange TSX More
  • Industry Biotechnology More
  • Sector Healthcare More
Trillium Therapeutics Inc. Logo Image
  • 11-50 Employees
  • Based in Mississauga, Ontario
Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. They have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a protective “do not eat” signal that blocks the ability of certain immune cells to destroy the tumor. By blocking this “do not eatMore” signal with decoy receptors, they aim to unmask tumor cells and make them visible to, and eradicated by, the immune system.
Trillium Therapeutics Inc.

Most Recent Annual Report

Trillium Therapeutics Inc. MOST RECENT 2019 Annual Report

Report Locked. Trillium Therapeutics Inc. has reached its limit for free report views.

Older/Archived Annual Reports